Bangkok--Dec 4--Pfizer Inc
Pfizer Inc said today that a revised product information label for Viagra, approved by the U.S. Food and Drug Administration, provides updated clinical information to assist doctors in the diagnosis and treatment of men with erectile dysfunction (ED).
The clinical experience for Viagra has been largely consistent with the safety and efficacy profile established in the scientific trials that were the basis for FDA approval, Pfizer said. However, based on post-marketing reports, the label has been revised to reflect new information including infrequent reports of priapism, which was not seen in the trials. Reviewing post-marketing experience and updating the labeling of new products is a routine process.
According to the FDA, “it is important to note that the post-marketing reports involving Viagra constitute only a small fraction of the more than six million prescriptions written for this drug. FDA continues to believe Viagra is safe and effective if used according to the updated labeling.”
The revised label reflects extensive safety data collected on a worldwide basis since April, when Viagra was introduced in the U.S. Since then, Viagra has been approved in more than 40 countries worldwide. In the U.S., Viagra has been prescribed to more than three million patients by about 200,000 physicians, providing safety reporting equivalent to two years’ experience for other new medicines.
The FDA stated that, “the new labeling is intended to help make sure that consumers and doctors are fully informed about the benefits and risks of using Viagra, know that consideration must be given to the cardiovascular status of patients prior to prescribing Viagra, and know how to safely use the drug.”
“Because ED is often a symptom of underlying diseases such as heart disease, diabetes and high blood pressure, we again emphasize that men with ED should see their doctor for a full clinical evaluation,” said Ms. Beyhan D. Zaim, General Manager, Thailand/Myanmar, Pfizer Pharmaceuticals. The exam should cover health issues related to the resumption of sexual activity, a form of physical exertion that increases the heart rate and cardiac workload.
“In Thailand, Viagra has been on sale for over three months and there have been no reported cases of deaths or serious adverse events to date”, noted Ms. Zaim.
The updated label provides further guidance to physicians for assessing cardiac risk in patients with pre-existing cardiovascular disease. More than 75 percent of the six million Viagra prescriptions have been written for patients between the ages of 50 and 80.
The revised U.S. label reflects infrequent post-marketing reports of priapism (painful erections greater than six hours in duration), including some patients who were using Viagra together with other erectile dysfunction treatments. Patients are advised to seek medical attention if this condition occurs.
Patients taking nitrates in any form should not take Viagra. Pfizer said it would continue educating health care professionals about this important contraindication, which was included in the product label at approval.
For further information, please contact Pongprach SurojnametakulDerrick Bartel Presko Shandwick (Thailand) Ltd. Tel: 273 8800 Fax: 273 8880 End.